中国对欧盟限制采购中国医疗器械发起反制

Core Viewpoint - The article discusses China's response to the European Union's restrictions on Chinese medical devices, highlighting the ongoing trade tensions and the implications for both parties in the medical equipment sector [1][12]. Group 1: EU Restrictions and China's Response - On June 20, the European Commission announced that Chinese companies would be excluded from EU public procurement projects exceeding €5 million, with a cap on subcontracting to Chinese entities or components at 50% of the total project value [1]. - This marks the first application of the EU's International Procurement Instrument (IPI) against specific countries since its introduction in June 2022, aimed at addressing perceived discrimination against EU enterprises [1][4]. - In response, China announced on July 6 that it would implement reciprocal measures to protect its enterprises and maintain fair competition [12][13]. Group 2: Growth of Chinese Medical Device Industry - From 2015 to 2023, China's exports of medical devices and equipment to the EU more than doubled, with an expected export value of $9 billion in 2024, reflecting a 12% year-on-year increase [3]. - Chinese companies have begun to enter high-end medical equipment markets, such as CT and MRI systems, demonstrating competitive capabilities through technological innovation [2]. - In the field of in vitro diagnostic reagents, Chinese firms have gained traction in Europe, particularly in grassroots healthcare and third-party testing laboratories, due to their diverse product lines and cost-effective solutions [2]. Group 3: Allegations and Criticism - A report claimed that the Chinese government promotes a "Buy China" policy, which supports domestic products while limiting imports, with a target for domestic medical devices to achieve a 70% market share in county-level hospitals by 2025 [5][6]. - The report also indicated that 87% of sampled Chinese public procurement projects contained direct or indirect restrictions on imported medical devices, with the proportion of tenders explicitly banning imports rising from 36% to 53% from 2022 to 2024 [7]. - The EU-China Chamber of Commerce criticized the IPI investigation's conclusions as unfair, asserting that the findings do not accurately reflect the reality of the Chinese medical procurement market [8].